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Improved detection of RNA foci in C9orf72
amyotrophic lateral sclerosis post-mortem
tissue using BaseScopeTM shows a lack of
association with cognitive dysfunction
Arpan R. Mehta,1,2,3,4,5 Bhuvaneish T. Selvaraj,1,2,4 Samantha K. Barton,2,4,6
Karina McDade,2,4 Sharon Abrahams,4,7 Siddharthan Chandran,1,2,3,4,8,9 Colin Smith,2,4,10,11
and Jenna M. Gregory1,2,4,10,11
The C9orf72 hexanucleotide repeat expansion is the commonest known genetic mutation in amyotrophic lateral sclerosis. A neuro-
pathological hallmark is the intracellular accumulation of RNA foci. The role that RNA foci play in the pathogenesis of amyo-
trophic lateral sclerosis is widely debated. Historically, C9orf72 RNA foci have been identified using in situ hybridization. Here,
we have implemented BaseScopeTM, a high-resolution modified in situ hybridization technique. We demonstrate that previous
studies have underestimated the abundance of RNA foci in neurons and glia. This improved detection allowed us to investigate the
abundance, regional distribution and cell type specificity of antisense C9orf72 RNA foci in post-mortem brain and spinal cord tis-
sue of six deeply clinically phenotyped C9orf72 patients and six age- and sex-matched controls. We find a correlation between
RNA foci and the accumulation of transactive response DNA-binding protein of 43 kDa in spinal motor neurons (rs ¼ 0.93;
P¼ 0.008), but not in glia or cortical motor neurons. We also demonstrate that there is no correlation between the presence of
RNA foci and the accumulation of transactive response DNA binding protein of 43 kDa in extra-motor brain regions.
Furthermore, there is no association between the presence of RNA foci and cognitive indices. These results highlight the utility of
BaseScopeTM in the clinicopathological assessment of the role of antisense RNA foci in C9orf72.
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Abbreviations: ALS ¼ amyotrophic lateral sclerosis; BA ¼ Brodmann area; C9orf72 ¼ chromosome 9 open reading frame 72;
DapB ¼ L-2,3-dihydrodipicolinate reductase; DNase ¼ deoxyribonuclease; ECAS ¼ Edinburgh Cognitive and Behavioural Screen;
fALS ¼ familial amyotrophic lateral sclerosis; ISH ¼ in situ hybridization; mRNA ¼ messenger RNA; PPIB ¼ peptidyl-prolyl cis-
trans isomerase B; RAN ¼ repeat-associated non-AUG; TDP-43 ¼ transactive response DNA-binding protein of 43 kDa
Introduction
A key post-mortem diagnostic hallmark of most amyo-
trophic lateral sclerosis (ALS) cases is the presence of
intra-cytoplasmic transactive response DNA-binding pro-
tein of 43 kDa (TDP-43) aggregates in motor cortex and
spinal cord motor neurons and glia, associated with an-
terior horn cell loss and gliosis (Arai et al., 2006;
Neumann et al., 2006). Additionally, we have previously
demonstrated widespread cortical TDP-43 (neuronal and
glial) aggregation in extra-motor cortical regions linked
to executive, language and fluency dysfunction (Gregory
et al., 2019).
Familial ALS (fALS) cases account for approximately
10% of all ALS cases; approximately 40% of fALS cases
and a proportion of sporadic cases are caused by the
C9orf72 hexanucleotide G4C2 repeat expansion, making
it the commonest known ALS genetic mutation (DeJesus-
Hernandez et al., 2011). Such patients typically present
with motor symptoms; however, cognitive dysfunction
(affecting all domains: fluency, language, executive and
behavioural functions) is common, as is a neuropsychi-
atric presentation (Abrahams et al., 2000; Goldstein and
Abrahams, 2013; Strong et al., 2017; Gregory et al.,
2019). Intracellular accumulation of sense and antisense
RNA foci is a key molecular hallmark in the CNS of
C9orf72 cases. Their precise pathogenic role is widely
debated (Vatsavayai et al., 2019); nevertheless, antisense
RNA foci have been shown to exert a greater deleterious
effect than sense RNA foci (Gendron et al., 2013; Zu
et al., 2013; Cooper-Knock et al., 2015; Aladesuyi
Arogundade et al., 2019) and antisense RNA foci, but
not sense RNA foci, correlate with TDP-43 aggregation
in C9orf72 motor neurons (Cooper-Knock et al., 2015;
Aladesuyi Arogundade et al., 2019).
It therefore remains an open question as to the role of
antisense RNA foci in extra-motor regions, and whether,
if present in these areas, they exert any effect on cogni-
tion. Moreover, parsing out the role of RNA foci in non-
neuronal cells, and in regions of the brain and spinal
cord that are not affected by TDP-43 pathology, remains
to be performed. To date, classical in situ hybridization
(ISH) techniques to investigate the abundance and clinico-
pathological relevance of RNA foci in human C9orf72
brain and spinal cord tissue (Gendron et al., 2013;
Mizielinska et al., 2013; Cooper-Knock et al., 2015;
DeJesus-Hernandez et al., 2017; Aladesuyi Arogundade
et al., 2019) have been limited by technical challenges
that have prevented these questions from being addressed.
First, owing to the substantial autolysis of mRNA in
post-mortem samples, ISH probes are impeded in their
binding to the target. Secondly, Sudan black tends to be
used to quench background autofluorescence, which has
the detrimental effect of also quenching signal. Thirdly,
there is a lack of resolution and/or sensitivity with conse-
quential inadequate cell type-specific resolution at low
magnification, mandating high-resolution imaging of
single cells or, in the case of C9orf72 RNA foci, single
nuclei at high resolution; this prevents informative com-
parative imaging and quantification of large areas of
tissue.
BaseScopeTM is a modified ISH technique that
addresses some of these limitations, allowing for greater
sensitivity and specificity, and achieves amplification of
Graphical Abstract
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mRNA with improved single-cell, single-transcript reso-
lution. The BaseScopeTM probes are designed to bind to
the mRNA transcript in several sets of probe pairs,
allowing for increased sensitivity and specificity. Probe
hybridization is followed by the addition of iterative
amplification probes, facilitating large numbers of mole-
cules of chromogen (rather than a single molecule in clas-
sical ISH) to bind to the probe. This serves to amplify
the (partially degraded, autolysed) mRNA transcript sig-
nal, thereby permitting the detection of single transcripts
at a single-cell level, even at low magnification.
Accordingly, this leads to improved spatial resolution, by
virtue of being able to image many cells at once, rather
than single cells. In addition, the use of chromogen detec-
tion with a haematoxylin counterstain to identify cells
obviates the need to use Sudan black to quench back-
ground autofluorescence and makes it possible to resolve
cell type-specific and subcellular localization of RNA foci.
We therefore aimed to use BaseScopeTM to visualize
C9orf72 RNA foci and hypothesized that the increased
resolution, sensitivity and specificity that this technique
confers would allow us to examine whether antisense
RNA foci are (i) associated with TDP-43 accumulation in
extra-motor brain regions and (ii) independently associ-
ated with cognitive deficits in these extra-motor brain
regions.
Materials and methods
Case identification and cognitive
profiling
We identified six ALS post-mortem cases with a C9orf72
hexanucleotide repeat expansion and six age- and sex-
matched control cases (with no neurological disorder
during life and no significant neuropathology present at
post-mortem; Table 1). Each donor patient had undergone
neuropsychological testing with the Edinburgh Cognitive
and Behavioural ALS Screen (ECAS; https://ecas.psy.ed.ac.
uk/; Abrahams et al., 2014). Additionally, all cases had
corresponding whole genome sequencing and diagnostic re-
peat prime polymerase chain reaction, demonstrating
pathogenic repeat lengths in the C9orf72 locus (Leighton
et al., 2019). All patients had consented to the use of their
data for research (Leighton et al., 2019). The use of
human tissue for post-mortem studies has been reviewed
and approved by the Edinburgh Brain Bank ethics commit-
tee and the Academic and Clinical Central Office for
Research and Development medical research ethics com-
mittee, in line with the Human Tissue (Scotland) Act
2006.
Brain region selection
To confirm the recently reported association between anti-
sense RNA foci and TDP-43 accumulation in motor
neurons (Cooper-Knock et al., 2015; Aladesuyi
Arogundade et al., 2019), we examined motor regions
including the anterior horn of the spinal cord and cortical
motor neurons in Brodmann area (BA) 4. These areas
have previously been examined for the presence of TDP-
43 accumulation, and the misfolded protein burden (based
on cells demonstrating aberrant phospho-TDP-43 immu-
noreactivity) was scored from mild to severe (Gregory
et al., 2019). Brain regions typically affected in ALS
patients experiencing cognitive deficits are the regions asso-
ciated with language, fluency and executive functions.
Thus, we selected a representative brain region associated
with language and fluency function (inferior frontal gyrus;
BA44/45) and a representative brain region associated
with executive function (dorsolateral prefrontal cortex;
BA46). We also examined the cerebellum for evidence of
RNA foci, since it does not typically have TDP-43 aggre-
gates but, unique to C9orf72 cases, demonstrates p62-posi-
tive inclusions (Al-Sarraj et al., 2011). These aggregates
are not associated with cell death or cell loss and co-stain
for dipeptide repeat proteins, which result as a direct con-
sequence of the repeat-associated non-AUG (RAN) transla-
tion of the C9orf72 repeat expansion (Gendron et al.,
2013).
BaseScopeTM in situ hybridization
Brain tissue was processed for BaseScopeTM as previously
reported (Gregory et al., 2019). We optimized the
BaseScopeTM technique on control tissue to address probe
specificity; CG-repeat probes will also bind to CG repeats
within the DNA, which exist in both control cases and
C9orf72 cases. Deoxyribonuclease (DNase) treatment
(optimized specifically to retain haematoxylin counter-
staining, but eliminate probe binding to DNA repeats)
was carried out at 40C at a concentration of 800U/ml
for 30min immediately following the protease III tissue
permeabilization step and prior to probe hybridization.
This limited probe hybridization to DNA repeats, thereby
preventing amplification of background binding to these
repeats. Probe hybridization was then performed by incu-
bating the slides with four drops of custom-designed
BaseScopeTM probe to identify antisense C9orf72 RNA
foci, negative control probe (L-2,3-dihydrodipicolinate re-
ductase, DapB) or positive control (peptidyl-prolyl cis-
Table 1 Clinical characteristics of cases included in this
study
C9orf72-ALS cases Control cases
Age at death (years) Median: 60; range:
43–63
Median: 59;
range: 41–63
Sex 3 males; 3 females 3 males; 3 females
Disease duration
(months)
Median: 44; range: 25–87 N/A
Age at onset (years) Median: 55; range: 38–60 N/A
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Figure 1 Motor neuronal—but not glial—RNA is associated with TDP-43 pathology. (A) Representative images of control (left
panel) and C9orf72 (right panel) anterior horn motor neurons (top panel) and glial cells (bottom panel). Images demonstrate negative staining for
antisense RNA foci in the control tissue and discrete antisense RNA foci (red dots) in motor neurons and glia of C9orf72 cases. Red arrows
indicate cells with positive staining, n ¼ 6 cases and six age- and sex-matched sudden death controls with no evidence of neurological disease.
Scale bars ¼ 40 mm. Residual background binding to DNA (small red dots) can be seen in controls and ALS cases; however, RNA foci are only
detected in C9orf72 cases (large red RNA foci). (B) Graph quantifying number of RNA foci per cell and the proportion of cells that contain RNA
foci in the anterior horn of the spinal cord; n ¼ 6 cases and six age- and sex-matched sudden death controls with no evidence of neurological
disease. Each bar represents a single case, error bars demonstrate variation between regions assessed within the pathological material analysed
for each case. (C) Representative images of control (left panel) and C9orf72 (right panel) cortical motor neurons (top panel) and cortical glial
cells (bottom panel). Images demonstrate negative staining for antisense RNA foci in the control tissue and discrete antisense RNA foci (red
dots) in motor neurons and glia of C9orf72 cases. Red arrows indicate cells with positive staining, n ¼ 6 cases and six age- and sex-matched
sudden death controls with no evidence of neurological disease. Scale bars ¼ 40 mm. Residual background binding to DNA (small red dots) can
be seen in controls and ALS cases; however, RNA foci are only detected in C9orf72 cases (large red RNA foci). (D) Graph quantifying number of
RNA foci per cell and the proportion of cells that contain RNA foci in the motor cortex; n ¼ 6 cases and six age- and sex-matched sudden death
controls with no evidence of neurological disease. Each bar represents a single case, error bars demonstrate variation between regions assessed
within the pathological material analysed for each case.
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trans isomerase, PPIB) probe for 2 h at 40C. The
FastRed chromogen incubation step was reduced from
10min to 2min. Sections were imaged at 40 magnifica-
tion on a NanoZoomer slide scanner (Hamamatsu), and
the relative abundance of transcripts was quantified
manually by neuropathologists assessing the proportion
of cells containing RNA foci and the mean (þ/ SD)
number of dots/transcripts per cell across 30 cells (10
cells in three randomly generated fields of view).
Statistical analysis
To assess for associations between antisense RNA foci
and TDP-43 pathology, we generated a compound prod-
uct score to reflect the number of foci per cell and the
proportion of cells affected by multiplying the mean val-
ues from the quantification of these two scores. We then
calculated the Spearman’s rank correlation coefficient,
inputting the TDP-43 score and the RNA foci product
score. Values were considered statistically significant
when P 0.05. Error bars represent variation within a
single case plotted as mean and standard error. Each bar
represents a single case.
Data availability
Data are available from the corresponding authors upon
reasonable request.
Results
BaseScopeTM permits improved
detection of antisense RNA foci in
C9orf72-ALS
The mean percentage of cells containing antisense RNA
foci in motor brain and spinal cord regions was 78.7%
for neurons and 24.9% for glia. The mean percentage of
cells containing antisense RNA foci in extra-motor brain
regions was 89.4% for neurons and 46.1% for glia. The
mean number of foci per cell in motor brain and spinal
cord regions was 2.6 for neurons and 1.1 for glia, and
the mean number of foci per cell in extra-motor brain
regions was 2.9 for neurons and 1.2 for glia. These data
illustrate the substantially improved signal amplification
and therefore the sensitivity of this technique when
compared with standard ISH techniques (Aladesuyi
Arogundade et al., 2019). This improved detection is
especially the case at low magnification, as illustrated in
the low-magnification images shown in Supplementary
Fig. 1, demonstrating clear staining of RNA foci (red
dots) without the need to examine a single nucleus at
higher magnification. The mean number of foci per cell is
comparable to previous estimates in motor neurons, high-
lighting the robustness of this finding in the light of
improved sensitivity (Mizielinska et al., 2013; Aladesuyi
Arogundade et al., 2019).
Antisense RNA foci are associated
with TDP-43 aggregation in spinal
motor neurons but not in motor
cortex or spinal cord glia
Previously, it has been shown that antisense RNA foci
are associated with TDP-43 pathology in spinal motor
neurons of C9orf72-ALS cases (Cooper-Knock J et al.,
2015; Aladesuyi Arogundade et al., 2019). Here, all six
cases demonstrated TDP-43 pathology in the motor neu-
rons of the spinal cord and motor cortex, and also dem-
onstrated concomitant neuronal antisense RNA foci
(Table 2; Fig. 1). In contrast, the association between
TDP-43 aggregation and the presence of antisense RNA
foci was not apparent in glial cells in the same regions.
Case 1 had no evidence of glial TDP-43 aggregation, but
a similar burden of antisense RNA foci to the other cases
that did demonstrate TDP-43 pathology. Moreover, the
examination of the remaining five cases revealed trends
in expression that also support this finding; Cases 2 and
4 appeared to have the most abundant neuronal TDP-43
pathology and correspondingly the highest abundance of
neuronal antisense RNA foci in both the spinal cord and
the motor cortex. Similarly, Case 5 had the least abun-
dant neuronal TDP-43 pathology and correspondingly the
least abundant levels of neuronal antisense RNA foci.
This association, with respect to trends in expression of
TDP-43 and the presence of antisense RNA foci, did not
hold true for the glial cells in the motor cortex and spi-
nal cord. To assess the association between the abun-
dance of RNA foci and TDP-43 aggregation in further
detail, we next calculated the Spearman’s rank correlation
coefficients to compare TDP-43 abundance to a product
score comprised of the percentage of RNA foci positive
Table 2 Scoring of regional TDP-43 pathology
Case Cell
type
BA4 Spinal
cord
BA44/45 BA46 Cerebellum
1 Neuron 2 2 1 1 0
Glia 0 0 0 0 0
2 Neuron 2 3 1 1 0
Glia 3 3 1 1 0
3 Neuron 1 2 0 1 0
Glia 2 2 0 0 0
4 Neuron 3 3 1 1 0
Glia 3 3 1 1 0
5 Neuron 1 1 1 1 0
Glia 2 2 1 2 0
6 Neuron 2 2 1 1 0
Glia 2 2 1 1 0
The table summarizes pathological TDP-43 staining using a phospho-TDP-43 antibody.
Scoring of TDP-43 pathology is based on the semi-quantitative scoring published previ-
ously (Gregory et al., 2019): 0—no evidence of TDP-43 pathology, 1—mild pathology,
2—moderate pathology and 3—severe pathology. Neuronal and glial pathology have
been quantified individually.
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Figure 2 Statistically significant correlation between TDP-43 abundance and RNA foci in spinal cord of C9orf72 patients.
Scatter plots of TDP-43 abundance on the abscissa and RNA foci product score (a function of number of foci and percentage of cells affected) on
the ordinate. Each point on the graph is an individual case. rs values were calculated using Spearman’s correlation, and values were considered
significant when P < 0.05. Data demonstrate that a correlation between RNA foci and TDP-43 exists only in motor neurons of the spinal cord in
C9orf72 patients.
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cells and the number of foci per cell for each of the brain
regions and spinal cord segments examined for both glial
and neuronal cell populations. This test demonstrated a
significant correlation for spinal motor neurons (rs ¼
0.93; P¼ 0.008), but not for spinal cord glia (rs ¼
0.32; P¼ 0.54), motor cortex neurons (rs ¼ 0.25;
P¼ 0.64) or motor cortex glia (rs ¼ 0.34; P¼ 0.51;
Fig. 2).
Antisense RNA foci are not
associated with TDP-43 aggregation
or clinical manifestations in
extra-motor brain regions
Given the association between TDP-43 pathology and
antisense RNA foci in spinal cord motor neurons, and
the association between TDP-43 and cognitive deficits in
ALS (Henstridge et al., 2017; Gregory et al., 2019), we
next sought to examine the relationship between TDP-43
and antisense RNA foci in extra-motor brain regions re-
sponsible for cognition. Importantly, all six cases exam-
ined in this study had cognitive testing during life using
the same screening tool—the ECAS. We have previously
documented the TDP-43 distribution of the six cases
assessed in this study (Gregory et al., 2019), demonstrat-
ing that the presence of TDP-43 pathology in brain
regions associated with executive function, language and
fluency is associated with cognitive deficits. None of the
cases examined in this study met the criteria for a diag-
nosis of frontotemporal dementia or had behavioural
symptoms. Three cases had mild language deficits, one
case had mild executive dysfunction and two cases had
normal cognitive function (Table 3). Despite having
marked differences in extra-motor clinical manifestations
(differentially affected subdomains of cognition), all cases
had a similar regional distribution and abundance of
RNA foci in extra-motor brain regions (Fig. 3).
Spearman’s rank correlation coefficient demonstrated no
significant correlation between antisense RNA foci in
BA44 neurons (rs ¼ 0.13093, P¼ 0.80473) or glia (rs ¼
0.20702, P¼ 0.69391) or BA46 glia (rs ¼ 0.77152,
P¼ 0.07234; Fig. 2). It was not possible to calculate a
correlation coefficient for BA46 neurons, since all of the
TDP-43 values were the same. Furthermore, we found
evidence of abundant RNA foci in all cell types of the
cerebellum, where there is an absence of any TDP-43
pathology (Fig. 4).
Discussion and Conclusions
Using a bespoke BaseScopeTM protocol, we build on pre-
vious studies that have implemented classical in situ tech-
niques, and confirm that antisense RNA foci are indeed
associated with TDP-43 pathology in spinal motor neu-
rons of C9orf72 cases (Cooper-Knock J et al., 2015;
Aladesuyi Arogundade et al., 2019). The advantage of
our novel methodology is that it affords appreciably
higher sensitivity and specificity when compared with
classical in situ hybridization, especially at low magnifica-
tion (Supplementary Fig. 1), resulting in greater identifica-
tion of the burden of antisense RNA foci than was
previously possible, including an examination for regional
and cell type specificity (Gendron et al., 2013;
Mizielinska et al., 2013; Cooper-Knock et al., 2015;
DeJesus-Hernandez et al., 2017; Aladesuyi Arogundade
et al., 2019).
Using this technique, we demonstrate that previous esti-
mates of antisense RNA foci, with a similar sample size
of C9orf72 cases (n¼ 5; Aladesuyi Arogundade et al.,
2019) are underestimates. Our data demonstrate that the
mean percentage of cells containing antisense RNA foci is
78.7% (cf. 20%) for neurons and 24.9% (cf. 1%) for
glia in motor regions and 89.4% for neurons and 46.1%
for glia in extra-motor regions.
Thus, we show the burden of antisense RNA foci on
glial pathology and that, unlike that for motor neurons,
antisense RNA foci present in glial cells both in the
motor cortex and the spinal cord do not associate with
TDP-43 pathology. We also show that there is no associ-
ation between TDP-43 pathology and antisense RNA foci
in extra-motor brain regions in neurons [in agreement
with Aladesuyi Arogundade et al. (2019) and Cooper-
Knock J et al. (2015)] and, for the first time, we demon-
strate this same finding also in glial cell populations.
Indeed, we identified antisense RNA foci of varying
abundance in all extra-motor brain regions, irrespective
of underlying TDP-43 pathology. Our cases had been
deeply clinically phenotyped in life and, as such, we
examined the influence of antisense RNA foci on cogni-
tive function using the ECAS, designed for, and validated
in, ALS (Abrahams et al., 2014; Niven et al., 2015).
Accordingly, we show, for the first time, through analysis
of cell type-specific antisense RNA foci staining, that glial
cells and neuronal cells examined in all brain regions
contained RNA foci, the abundance of which did not
Table 3 Cognitive profile of the cases included in this
study
Case ECAS
total
Executive Fluency Language Disease
duration
(months)
1 102 31 18 27 97
2 112 39 20 26 58
3 102 35 18 23 58
4 100 36 18 20 60
5 114 39 16 28 109
6 118 40 18 28 33
The table summarizes cognitive scores for each of the cases included in this study.
Scores reflect total ECAS (which are not significantly impaired for all individuals) and
subdomain scores. Boxes highlighted in bold are indicative of a score that falls below
the normal threshold according to published cut-offs. Therefore, bold-highlighted
boxes indicate a mild cognitive deficit in the specified ECAS subdomain.
RNA foci detected using BaseScopeTM in C9orf72-ALS BRAIN COMMUNICATIONS 2020: Page 7 of 10 | 7
Figure 3 Absence of association between presence or abundance of RNA foci and clinical manifestations or TDP-43 pathology
in extra-motor regions. (A) Representative images of control (left panel) and C9orf72 (right panel) neurons of BA44 brain region associated
with language and fluency dysfunction (top panel) and glial cells (bottom panel). Images demonstrate negative staining for antisense RNA foci in
the control tissue and discrete antisense RNA foci (red dots) in neurons and glia of C9orf72 cases. Red arrows indicate cells with positive
staining, n ¼ 6 cases and six age- and sex-matched sudden death controls with no evidence of neurological disease. Scale bars ¼ 40 mm. Residual
background binding to DNA (small red dots) can be seen in controls and ALS cases; however, RNA foci are only detected in C9orf72 cases (large
red RNA foci). (B) Graph quantifying number of RNA foci per cell and the proportion of cells that contain RNA foci in BA44; n ¼ 6 cases and six
age- and sex-matched sudden death controls with no evidence of neurological disease. Each bar represents a single case, error bars demonstrate
variation between regions assessed within the pathological material analysed for each case. (C) Representative images of control (left panel) and
C9orf72 (right panel) neurons of BA46 brain region associated with executive dysfunction (top panel) and cortical glial cells (bottom panel).
Images demonstrate negative staining for antisense RNA foci in the control tissue and discrete antisense RNA foci (red dots) in neurons and glia
of C9orf72 cases. Red arrows indicate cells with positive staining, n ¼ 6 cases and six age- and sex-matched sudden death controls with no
evidence of neurological disease. Scale bars ¼ 40 mm. Residual background binding to DNA (small red dots) can be seen in controls and ALS
cases, however RNA foci are only detected in C9orf72 cases (large red RNA foci). (D) Graph quantifying number of RNA foci per cell and the
proportion of cells that contain RNA foci in BA46; n ¼ 6 cases and six age- and sex-matched sudden death controls with no evidence of
neurological disease. Each bar represents a single case, error bars demonstrate variation between regions assessed within the pathological
material analysed for each case.
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vary with differing clinical phenotypes, for example: cog-
nition, disease duration or extent of regional involvement.
Notably, this is also the case for TDP-43 pathology.
While the presence of TDP-43 proteinopathy is associated
with clinical manifestations of both FTD and ALS, the
abundance of TDP-43 pathology is not related to clinical
severity (Cykowski et al., 2017). We cannot rule out the
possibility of there having been mismatch cases (defined
as cases with antisense RNA foci but no clinical manifes-
tations as we have seen previously with TDP-43 path-
ology; Gregory et al., 2019).
Taken together, we demonstrate the utility of a sensitive
and specific method for easily identifying antisense RNA
foci in C9orf72-ALS brain and spinal cord tissue, conclud-
ing that there is no association between the abundance or
presence of antisense RNA foci in extra-motor brain regions
of patients with C9orf72-ALS and their cognitive ability.
Study limitations
A limitation of studies assessing post-mortem samples
that are associated with cognitive data obtained via the
same cognitive screening tool is the small sample size.
We identified six cases for examination in this study; a
larger sample size would afford the power to detect more
subtle clinicopathological correlations. Notwithstanding
this small sample size, we were able to demonstrate a
statistically significant correlation between antisense RNA
foci and TDP-43 aggregation in spinal motor neurons. Of
course, we cannot exclude the possibility that in other
brain regions there may be more subtle correlations for
which we did not have the power to detect.
Furthermore, we appreciate that it would be useful to
demonstrate TDP-43 aggregation and antisense RNA foci
in the same cells in a single tissue section; however, likely
due to the large size of the RNA foci and amplification
cassette used in the BaseScopeTM technique, the TDP-43
antibodies are not able to enter the cytoplasm due to
steric hindrance, which is why we chose to score the
pathologies separately, in line with previous studies. This
is a key area for development in molecular pathology,
which would improve the accuracy of clinicopathological
correlations such as these.
Supplementary material
Supplementary material is available at Brain
Communications online.
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